announces the launch of Cinacalcet Hydrochloride Tablets in US market, the company said in the filing on Wednesday after market hours.
The pharma company has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc, Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets.
Cinacalcet Hydrochloride tablets had an annual sale of ~US$1,449 mn for the twelve months ending May 2019 as per IQVIA.
Aurobindo Pharma Ltd is currently trading at Rs604.50 up by Rs7.1 or 1.19% from its previous closing of Rs597.40 on the BSE.
The scrip opened at Rs603.10 and has touched a high and low of Rs609 and Rs602.90 respectively.